Kalaris Therapeutics KLRS
NASDAQ KLRS
$2.18 +0.11 (+5.69%)
As of: Oct 21, 2026 · 10:58 AM EDT

Kalaris Therapeutics (KLRS) Notes Payables (2024)

Updated

Kalaris Therapeutics (KLRS) recorded Notes Payables of $19.54 million in Q4 2024.

Analysis

Kalaris Therapeutics (KLRS) Notes Payables (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,129.91 Bn 1,098.50 Bn 19.71 Bn
2 Johnson & Johnson 613.69 Bn 532.22 Bn 17.26 Bn
3 AbbVie 503.05 Bn 476.16 Bn 12.70 Bn
4 Merck 367.72 Bn 322.10 Bn 12.21 Bn
5 Novartis Ag 297.87 Bn 261.86 Bn 11.24 Bn
6 Astrazeneca 261.30 Bn 234.99 Bn 12.86 Bn
7 Amgen 235.86 Bn 191.25 Bn 7.24 Bn
8 Gilead Sciences 190.51 Bn 164.71 Bn 6.22 Bn
9 Pfizer 169.83 Bn 116.48 Bn 10.94 Bn
10 Kalaris Therapeutics 51.93 Mn -41.57 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 19.54 Mn
API Access

Kalaris Therapeutics Notes Payables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=notes-payables&ticker=KLRS&period=max&api_key=YOUR_API_KEY